Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Consultant-Needed-Insert
    X

    Find Novel Dermatology Drugs in Clinical Development

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Sirona Biochem Corp

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields

              Contact the Supplier

              Lead Product(s): Difluorocyclohexyloxyphenol

              Therapeutic Area: Dermatology Product Name: TFC-1067

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 16, 2020

              Details:

              Sirona has made its first shipment of compound, TFC-1067 to Rodan + Fields. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia.

              Revance Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

              Contact the Supplier

              Lead Product(s): OnabotulinumtoxinA

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mylan Inc.

              Deal Size: $100.0 million Upfront Cash: $25.0 million

              Deal Type: Licensing Agreement June 01, 2020

              Details:

              Mylan has decided to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX® and BOTOX® Cosmetic (onabotulinumtoxinA), the market-leading neuromodulator.

              Crescita Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Crescita Awarded Cannabis Research License from Health Canada

              Contact the Supplier

              Lead Product(s): Cannabinoid based products

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2020

              Details:

              The cannabis research license by Health Canada allows the Crescita to possess cannabis for the purpose of research and development.

              Sirona Biochem Corp

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067

              Contact the Supplier

              Lead Product(s): TFC-1067

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 22, 2020

              Details:

              TFC-1067 demonstrated very good skin compatibility and does not show a sensitizing effect.

              WuXi Biologics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Almirall and WuXi Biologics sign strategic collaboration agreement for multiple bispecific antibodies targeting dermatology diseases

              Contact the Supplier

              Lead Product(s): Bispecific antibody

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: ALMIRALL

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 09, 2020

              Details:

              With this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis.

              23andMe

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL...

              Contact the Supplier

              Lead Product(s): Bispecific antibody

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: ALMIRALL

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 09, 2020

              Details:

              Almirall will secure the rights to develop and commercialize the antibody for worldwide use. This agreement will strengthen Almirall's early-stage research portfolio.

              PharmaCompass__DigitalAd